Selecting the Best CyberKnife Surgeons and Hospitals in India: A Guide for Patients from Iraq

Author:- Dr. Dheeraj Bojwani Date Created:- 19-08-2026

Over the years, I have fielded a specific kind of question from Iraqi families researching CyberKnife treatment: they have usually already read a hospital’s marketing page quoting one impressive success percentage, and they call me to ask whether it is genuinely accurate. In my experience of 24 years advising patients through exactly this decision, the honest answer is almost always the same: the number is probably real, but it very likely describes a specific tumour type, a specific follow-up period, and a specific level of complexity that may or may not match your actual case. CyberKnife is a genuinely precise technology, but precision in marketing language is a different thing from precision in radiation delivery, and this guide is designed to help you tell the two apart.

Healing Journeys of Iraqi Patients

Iraqi Patients Share Their Experience

Why the Choice of Radiation Oncology Team in India Matters as Much as the Choice of Technology

Based on my interactions with international patients, published clinical data on CyberKnife makes one thing very clear: outcomes are highly specific to tumour type, location, and how long after treatment a patient is followed. A published series treating lung metastases with CyberKnife reported local tumour control of 97.6 percent at one year, still a strong 90.6 percent at two years, and 87 percent at three years, a gradual decline over time that is entirely normal and expected for this kind of data, but one that a hospital quoting only the one-year figure would present very differently from a hospital being fully transparent about longer follow-up. Other published series treating different tumour types, including spinal metastases, recurrent brain tumours, and rare vascular tumours of the central nervous system, report meaningfully different control rates, in some cases considerably lower, particularly for tumours that have already recurred after previous treatment or that sit in technically difficult locations near critical structures. One published series of recurrent medulloblastoma, for instance, reported three-year local control of only 65 percent overall, with outcomes differing further between paediatric and adult patients. This is precisely why the specific tumour type, location, and treatment history in your case, not a single headline percentage borrowed from a different situation entirely, should shape your expectations before you travel.

How Patients from Iraq Can Verify a CyberKnife Hospital’s Accreditation in India

The fastest filter I recommend to every Iraqi family calling about CyberKnife is verifiable accreditation, not marketing language. Joint Commission International, JCI, audits a hospital’s overall clinical safety systems against the same standard used across the United States and Europe. The National Accreditation Board for Hospitals and Healthcare Providers, NABH, is India’s own domestic equivalent, and in my experience of 24 years advising families on this exact decision, a centre holding both marks together is a meaningfully stronger signal than either alone. For CyberKnife specifically, ask one further, very direct question: how many years has this specific machine been in clinical operation at this hospital, and how many CyberKnife cases has the treating radiation oncology team actually delivered, since owning the equipment and having deep clinical experience with it are two different things entirely.

CyberKnife Volume and Case-Complexity Criteria That Predict Outcomes in India

Based on my interactions with dozens of radiation oncology programmes over the years, a centre’s specific experience with your exact tumour type and its specific location is one of the clearest predictors of a good outcome, considerably more informative than the total number of CyberKnife treatments performed across every indication combined. Ask directly, in writing:

1. How many CyberKnife cases has this centre treated specifically for my tumour type and location, not simply a total case count across every indication treated?
2. What local tumour control rate does the centre report for this specific tumour type, and at what follow-up interval, one year, two years, or longer?
3. Is my case a first treatment or a case involving prior surgery, prior radiation, or recurrence, and how does the centre's own data reflect outcomes specifically for cases like mine?
4. Who reviews the treatment plan before delivery, a single radiation oncologist or a full multidisciplinary tumour board including a medical physicist?

A centre confident in its own outcomes will answer these specifically and promptly. A centre that responds only with a single blended success percentage regardless of tumour type or complexity deserves a second opinion before you commit.

Vetting a CyberKnife Hospital in India: A Guide for Patients from Iraq

Questions Patients from Iraq Should Ask About the CyberKnife Team in India

CyberKnife treatment planning is never genuinely the work of one person alone. In my experience of 24 years watching these programmes operate, the strongest units bring together a radiation oncologist to determine the overall treatment strategy, a medical physicist to plan and verify the precise radiation dose distribution, and, depending on the tumour type, a neurosurgeon, thoracic surgeon, or other relevant specialist to confirm that CyberKnife is genuinely the right tool for your specific case rather than conventional radiotherapy or surgery. A dosimetrist is often involved as well, working alongside the physicist to fine-tune exactly how the radiation beams are arranged around the tumour while sparing surrounding healthy tissue, a technical step that directly affects both how well the tumour responds and how few side effects the patient experiences afterward. Ask specifically who fills each of these roles for your case, and confirm that your imaging and treatment plan have been reviewed by more than one specialist before treatment begins, rather than finalised by a single radiation oncologist working alone.

CyberKnife Technology and Planning Standards in India That Patients from Iraq Should Check

The specific technology generation and planning process available changes what a centre can safely and precisely achieve. Ask whether the specific CyberKnife system at the hospital includes real-time tumour tracking for tumours that move with breathing, such as lung or liver tumours, since this capability directly affects treatment accuracy for these specific locations and is a meaningfully more advanced feature than static targeting alone. Ask how many treatment sessions your specific case will require and why, since CyberKnife is typically delivered over one to five sessions depending on tumour type and location, and a plan significantly outside this range for a straightforward case deserves an explanation. Ask also whether the centre has specific experience combining CyberKnife with other treatments, such as immunotherapy or targeted drug therapy, for cases where a combined approach has shown benefit in published research, since a centre limited to CyberKnife alone may not offer the fullest range of options for a complex case. Ask directly which of these specific capabilities apply to your case, not simply whether the hospital owns the equipment somewhere in the building.

Red Flags Patients from Iraq Should Watch For When Choosing a CyberKnife Hospital in India

Over the years, certain patterns have become reliable warning signs for me. A hospital that quotes a single success percentage without specifying tumour type, location, and follow-up interval has given you a number without the context needed to interpret it honestly. A centre that cannot state its own specific experience with your exact tumour type, offering only a total case count across all indications, has not demonstrated the specific expertise your case actually needs. And a centre that recommends CyberKnife without first confirming, through a genuine multidisciplinary review, that it is more appropriate than surgery or conventional radiotherapy for your specific situation deserves closer questioning before you proceed.

Factors Every Patient from Iraq Should Weigh Before Choosing CyberKnife Treatment in India

A Closing Thought for Iraqi Families

CyberKnife is a genuinely precise and valuable technology for the right tumour type and location, and it deserves a treatment team that explains honestly which category your case falls into and what outcome data actually applies, rather than a single optimistic percentage detached from your specific situation. Based on my interactions with international patients over more than two decades, the families who ask about tumour-specific control rates, follow-up intervals, and genuine multidisciplinary review consistently arrive at treatment better informed than those who accept a general marketing claim at face value. My role, and the role of any advisor a family works with, should be to help you ask these exact questions and confirm honestly that the specific team and specific hospital in front of you are the right fit for your family’s exact diagnosis. Iraq’s families deserve the same standard of scrutiny in this decision as any family anywhere else in the world.

Sources & Further Reading

• Joint Commission International (JCI) — Accredited Organizations Directory (jointcommissioninternational.org)
• National Accreditation Board for Hospitals & Healthcare Providers (NABH), India (nabh.co)
• PubMed Central — Clinical Outcomes of CyberKnife Stereotactic Radiosurgery for Lung Metastases (pmc.ncbi.nlm.nih.gov)
• PubMed Central — CyberKnife Radiosurgery for Recurrent Cranial Medulloblastomas (ncbi.nlm.nih.gov/pmc)
• American Society for Radiation Oncology (ASTRO) — Stereotactic Radiosurgery Patient Information (astro.org)

Frequently Asked Questions by Iraqi Patients about Selecting a CyberKnife Surgeon and Hospital in India